Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gentle electric current ease long COVID muscle pain?

NCT ID NCT06723821

Symptom relief Sponsor: University of Alcala Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a gentle, noninvasive microcurrent treatment can reduce muscle pain in people who had COVID-19. Forty adults with post-COVID musculoskeletal pain were randomly assigned to receive either real or sham microcurrent therapy for 12 sessions. Researchers measured pain intensity, sleep quality, anxiety, and quality of life to see if the treatment helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
microcurrent therapy (noninvasive neuromodulation)
What this could lead to
If it works, this could offer a drug-free way to reduce pain and improve sleep and quality of life for people with lingering post-COVID muscle pain.
What could go wrong
This is a small, early-stage trial with only 40 participants. The sham group may also improve, and results may not apply to everyone with post-COVID pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Dec 2024

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Positive result in PCR or antigen test for detecting COVID-19 in the last 3 months. * Present musculoskeletal pain in the last 3 months. * Age between 18 to 65 years old. * Score equal or superior to 4 in DN4 scale. Exclusion Criteria: * Present musculoskeletal pain of traumatic origin or known cause * Present musculoskeletal pain with more than 3 months of evolution. * Pregnant women * Present of vascular alterations, malignancy, thrombophlebitis or fever.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19 Musculoskeletal Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 Musculoskeletal pain

Contacts and locations

Locations

  • Centro Investigación Fisioterapia y Dolor

    Alcalá de Henares, Madrid, 28805, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.